AbbVie To Acquire Allergan In $63B Deal

Drugmaker AbbVie Inc ABBV has reached a deal to acquire Allergan AGN for $63 billion.

Allergan shareholders will receive 0.8660 AbbVie shares and $120.30 in cash for each Allergan share, for a total of $188.24 per Allergan share.

The acquisition will provide annual pre-tax synergies and other cost reductions of at least $2 billion in year three.

"AbbVie is expected to generate significant annual operating cash flow, which will support a debt reduction target of $15 to $18 billion before the end of 2021, while also enabling a continued commitment to Baa2/BBB or better credit rating and continued dividend growth," the companies said in a press release.

AbbVie shares traded down 8.22% at $72 in Tuesday's pre-market session. Allergan shares traded higher by 29.6% at $167.88.

Related Links:

The Daily Biotech Pulse: Genfit NASH Drug In China, Conatus Explores Sale

7 Stocks To Watch For June 25, 2019

Photo courtesy of Allergan.

Posted In: M&ANewsHealth CareTop StoriesGeneral
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...